Form 4: Akoya Biosciences CEO Reports Final Stock Transactions Post-Quanterix Merger
Insider Transaction Report
Akoya Biosciences, Inc. President and CEO Brian McKelligon reported the final disposition of his common stock and derivative securities in Akoya Biosciences following its merger with Quanterix Corporation on July 8, 2025.
Summary
- Brian McKelligon, President and CEO of Akoya Biosciences, Inc., reported changes in his beneficial ownership of Akoya Biosciences securities.
- The transactions occurred on July 8, 2025, which was the closing date of the merger between Akoya Biosciences, Inc. and Quanterix Corporation.
- Under the terms of the Amended and Restated Agreement and Plan of Merger dated April 28, 2025, Akoya Biosciences became a wholly-owned subsidiary of Quanterix Corporation.
- Each outstanding share of Akoya Biosciences common stock was converted into the right to receive 0.1461 shares of Quanterix common stock and $0.38 in cash.
- Options to purchase Akoya Biosciences common stock with an exercise price less than the per share merger consideration were accelerated and automatically cashless exercised.
- Options with an exercise price equal to or greater than the per share merger consideration were accelerated and automatically terminated and cancelled for no consideration.
- Following these transactions, Brian McKelligon's direct beneficial ownership of Akoya Biosciences common stock is 0 shares.
Sentiment
Score: 6
Explanation: The sentiment is moderately positive. While some options were terminated for no consideration, the overall transaction represents a completed merger where the reporting person's shares were converted into a combination of stock and cash, indicating a successful strategic exit for Akoya Biosciences shareholders.
Positives
- Options with exercise prices below the merger consideration were cashless exercised, allowing the reporting person to realize value from those options.
- The completion of the merger indicates a strategic transaction for Akoya Biosciences, with its shares converted into Quanterix stock and cash for shareholders.
Negatives
- Options with exercise prices equal to or greater than the per share merger consideration were terminated and cancelled for no consideration, resulting in a loss of potential value from those specific options.
Future Outlook
NA
Industry Context
This Form 4 filing reflects the completion of a significant M&A event in the life sciences or diagnostics industry, where Akoya Biosciences, a company focused on spatial biology solutions, was acquired by Quanterix Corporation, a company specializing in ultra-sensitive biomarker detection. Such mergers are common in the rapidly evolving biotech and diagnostics sectors as companies seek to consolidate technologies, expand market reach, and achieve synergies.
Stakeholder Impact
- Shareholders of Akoya Biosciences: Their shares were converted into Quanterix common stock and cash as part of the merger consideration.
- Employees (specifically option holders): Options were either cashless exercised or terminated based on their exercise price relative to the merger consideration.
Key Dates
| Date | Description |
|---|---|
| 2025-04-28 | Date of the Amended and Restated Agreement and Plan of Merger between Quanterix Corporation, Wellfleet Merger Sub, Inc., and Akoya Biosciences, Inc. |
| 2025-07-08 | Closing Date of the merger between Akoya Biosciences, Inc. and Quanterix Corporation, and the date of the reported transactions. |
| 2025-07-10 | Date Brian McKelligon signed the Form 4 filing. |
| 2027-11-09 | Expiration date of Employee Stock Options with an exercise price of $0.3029, which were disposed of. |
| 2029-05-02 | Expiration date of Employee Stock Options with an exercise price of $0.4427, which were disposed of. |
| 2031-03-24 | Expiration date of Employee Stock Options with an exercise price of $16.12, which were disposed of. |
| 2032-03-23 | Expiration date of Employee Stock Options with an exercise price of $11.88, which were disposed of. |
| 2033-02-23 | Expiration date of Employee Stock Options with an exercise price of $12.3, which were disposed of. |
| 2034-02-22 | Expiration date of Employee Stock Options with an exercise price of $5.35, which were disposed of. |
Keywords
Akoya Biosciences, Quanterix Corporation, Brian McKelligon, SEC Form 4, Merger, Stock Transaction, Insider Trading, Beneficial Ownership, Equity Securities, Stock Options, Cashless Exercise, Corporate Acquisition
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.